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Today mankind is experiencing an epidemic of 
opportunistic infections, among which mycoses take one 
of the leading places. Representatives of Candida genus 
are the most often causative agents of mycoses. 
Candidiasis is an opportunistic mycosis, which proceeds 
with lesions of the mucous membranes and the skin; 
disseminated forms, more often with the pulmonary 
involvement and gastrointestinal disorders, can be in 
patients with severe immunodeficiency states [1-5]. 
According to the international research the fungi of this 
genus are in the forth place in importance among 
infectious agents in the USA [6-9]. Only coagulase-
negative and coagulase-positive staphylococci and 
enterococci are ahead of them. A similar situation occurs 
in the countries of the former Soviet Union. From the 
abovementioned data it follows that trends with 
candidemia are approximately similar in countries of the 
Eastern and Western Hemisphere by the epidemic 
characteristics (including the species ratio of pathogens). 
Unfortunately, due to the absence of opportunistic 
mycoses recording in the registration cards of the 
Ministry of Health in the Russian Federation there are no 
statistic data on deep mycoses, including candidemias. 
But, however, according to the sporadic data that include 
the experience of clinicians – mycologists of the 
Research Institute of Medical Mycology named after 
P.N. Kashkin at St-Petersburg Medical Academy of 
Postgraduate Studies, who consult a number of medical 
institutions having the patients with invasive fungal 
infections, in particular fungemia, the number of cases of 
nosocomial mycoses, candidemias approximately 
corresponds to the data published in the USA [2, 10-12]. 
This is largely due to the fact that there are similar risk 
factors in the world that are the cause of occurrence of 
candidiases and candidemias (as well as other mycoses 
and fungemias). 
The genus of Candida indudes about 163 
species, but the main role in the pathological states of the 
human is played by the limited number of them; they are 
С. tropicalis, С. parapsilosi, С. glabrata, С. krusei, С. 
albicans with a significant predominance of the latter [2-
3, 8, 11]. Fungi of the genus Candida easily stained with 
methylene blue, and Gram-Himozoyu Romanovsky 
(picture 1). 
It should be noted that fungi of this genus are 
the component of the human normal intestinal and 
mucous membranes microflora [2, 4-5, 11]. Disturbance 
of the body’s microbial cenosis caused by the inadequate 
use of drugs of a wide range or changes in the 
microenvironment stimulates the excessive growth of 
Candida genus fungi [1-2, 9]. Metabolic and hormonal 
disorders (for example, diabetes mellitus, pregnancy, as 
well as intake of oral contraceptives) also contribute to 
development of candidiasis. 
 
 
Picture 1. World microscopy fungus C. albicans 
(Gram staining). 
 
Immunodeficiency states and administration of 
immunodepressants (for example, glucocorticoids) can 
cause different forms of candidiasis of the skin and 
mucous membranes or if the conditions, in which a 
person works or lives, contribute to the development of 
candidal infections (high humidity, fever, frequent 
contact with antibiotics or other chemical substances) [2-
3, 5, 12]. Candidiasis is characterized by intensive 
growth of these fungi, displacement of other 
representatives of the human normal microflora. In 
disseminated lesions it is formation of foci of necrosis 





Picture 2. Candidiasis 
 
The absence of rapid, sensitive and specific 
methods for diagnosis of invasive mycoses is a serious 
drawback in the treatment of such patients, and that is 
why a lot of persons die before receiving the adequate 
therapy [2, 8]. 
Diagnostic and therapeutic problems along with 
the successful use of antibacterial antibiotics in patients 
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with fever and neutropenia became the basis for carrying 
out the first two randomized studies of antifungal drugs 
in the 80-ies of the last century. It means empirical 
therapy of patients with fever and neutropenia when the 
antibacterial therapy is not effective; it is considered that 
the most obvious cause of such state of the patients is an 
undiagnosed fungal infection – usually candidiasis or 
aspergillosis [2, 4, 8, 11], and delay in treatment may end 
fatally. Thus, in our time the antifungal therapy is 
“blind”, i.e. without an accurate diagnosis of the fungal 
infection. The rational empirical antifungal therapy is the 
treatment of invasive fungal infection at a very early 
stage of the patient’s disease when there is a high risk of 
such infection [2, 4, 11]. 
Knowledge of a doctor and the state of a patient 
play an important role in the choice of the common 
correct approach concerning the treatment of every 
patient suffering from candidemia or different forms of 
invasive disseminated candidiasis. However, the choice 
of antifungal drugs between Fluconazol, some azoles and 
polyene amphotericin В is small. Besides, there are a lot 
of data concerning the loss of Candida genus fungi 
sensitivity to traditional antifungal drugs used for 
decades [1, 2, 4, 7, 9].  
The alternative direction to fight against 
candidal infection is to develop immunobiological drugs 
for treatment and prevention of candidiases. 
Various vaccines with the antigens of Candida 
genus fungi in their composition belong to these drugs 
[13-17]  
Development of technologies for obtaining 
antigens of Candida genus fungi began from the end of 
the last century. Whole cells of fungi were the first 
antigens. They possess the most complete antigenic 
properties [2, 18-20]. Researchers used filtrates of the 
culture fluid or filtrates of washings of fungal cells from 
a dense nutritional medium as antigens. The obtained 
fungal cells were inactivated by various methods: some 
researchers used physical methods such as heating, 
ultrasonic treatment, etc., other researchers applied 
chemical methods such as formolation, treatment with 
alcohol, etc. 
Later on researchers found more appropriate to 
use extracts from the destroyed fungal cells for obtaining 
antigens. Various methods – mechanical, physical, 
chemical and biological ones were used to disintegrate 
cells [2, 21-23]. Antigens consisted of fractions of the 
protein and glycoprotein nature. Each species of Candida 
had antigenic components of the glycoprotein nature that 
were common with other species and specific for the 
particular species. Lipid substances in the drugs obtained 
were presented in minimal quantities and probably in 
combination with proteins [2, 24, 25, 26]. 
The interest to mechanical methods of 
disintegration of Candida cells increased even more in 
connection with the research of the chemical 
composition and the antigenic structure of the isolated 
cell walls of fungi [2, 21, 23, 27, 28]. Antigenic drugs 
were prepared by the physical methods of cell 
destruction – autoclaving, freezing and thawing in 
different modes, electrolysis of cells in saline solution, 
ultrasound; by the chemical methods – by water-alcohol 
mixture, diethylene glycol, glycerin; surfactants 
(detergents) were also used [2, 21, 24, 26]. 
Isolation of antigens with the help of chemical 
extractants began in the 20-ies. Most researchers tried to 
obtain antigens by several methods and compare their 
chemical composition and activity. Some researchers 
preferred the cold water-alcohol extraction, others used 
the cell autoclaving with alcohol precipitation, and still 
others performed the extraction with trichloroacetic acid 
[2, 23, 25, 27]. The works of a number of researchers by 
the end of the 50-ies revealed that extracts composed 
mainly of carbohydrate components – polysaccharides 
had the greatest activity [2, 21, 22, 27]. The next period 
of time was devoted to the search of methods for 
isolation of polysaccharides, their purification, the study 
of biochemical characteristics and activity. 
Before the 60 - 70-s the new data were obtained 
while studying the structure of the cells of Candida 
genus fungi and the chemical composition of the cell 
components. It was found that the main part of 
hydrocarbon components of cells were in the membrane 
[2, 21, 23, 27]. It was logical to assume that 
polysaccharides obtained by different impact on the 
whole cell were isolated from the membrane. Thus, 
researchers began to study carefully the isolated cell 
walls. 
Some researchers fractionated decontaminated 
cell walls treating them with 1 N solution of potassium 
hydroxide [2, 22, 27]. Currently such methods of 
disintegration as shaking cells with glass beads in 
disintegrators, crushing the cell mass by a pressure 
machine, destruction of cells by ultrasound, etc., are used 
to obtain isolated cell walls [2, 21, 25]. It has been found 
that in sequential extraction of antigenic substancesfrom 
Candida genus fungi the specificity and activity of 
isolated drugs decrease with the increase of the 
hydrolyzing agent rigidity [2, 23, 27]. 
Some researchers have gone beyond the study 
of polysaccharides of the cell wall, and investigated 
extracellular polysaccharides of Candida genus fungi, 
which are present in the culture fluid. Extracellular 
polysaccharides are presented mainly by mannan, while 
in the cell wall there are glucan and mannan. It is 
connected with the solubility of mannan. Extracellular 
mannans and cell wall mannans do not differ 
immunochemically, structurally a cell wall mannan is 
more branched. The comparison of extracellular and 
intracellular purified mannans and mannan-proteins has 
shown that a mannan-protein has a greater activity and 
specificity than a pure mannan considered earlier to be 
independently responsible for the activity of antigenic 
drugs [2, 21, 24, 27]. 
Extracellular polysaccharides – mannan, have 
less complex structure, low molecular weight and do not 
form the complex compounds with proteins and lipids. 
Polysaccharides of the cell wall of Candida genus fungi 
are high-molecular and complexing. Glucan is insoluble 
in alkali, provides the form and constancy of the cell 
size, is partially soluble in water. Mannan has a branched 
structure, is soluble in water, easily isolated by various 
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methods of extraction of cell walls and the whole cells. 
Mannan is responsible for the antigen activity and cell 
specificity of yeast fungi. Their structure is similar in 
various species of Candida genus fungi and some other 
fungal genuses, and it provides cross reactions. Amino 
sugar – glucosamine, may play a role of a link in the 
membrane between proteins and polysaccharides. 
According to the opinion of many researchers, 
polysaccharides are in the cell wall as the mannan-
glucan-protein, mannan-protein and glucan-protein 
complex. The attempt of the maximum purification of 
the Candida genus fungi mannan, that is responsible for 
the antigenic activity, from other biochemical 
components of the cell, in particular destruction of the 
complex of polysaccharides with protein, does not 
increase the activity of antigenic drugs, and decrease 
their specificity [2, 21-22, 27]. 
Thus, up to the 80 – 90-s the data were 
obtained, according to which polysaccharides with 
Candida genus fungi could be divided into 4 groups by 
their localization in the cell: 1) noncellular 
polysaccharides released into the environment, 2) soluble 
or “structural-metabolic” polysaccharides of the cell 
walls, 3) insoluble or “structural” polysaccharides of the 
membranes, 4) intracellular or “reserve” polysaccharides 
[2, 23, 26, 28].  
However, all further studies concerning 
development of vaccines for prevention and treatment of 
candidal infection in Ukraine stopped since the collapse 
of the Soviet Union. A difficult and uncertain economic 
and political situation in the country has negatively 
impacted on all industries of Ukraine, and only now the 
work in this field partially begins. It should be noted that 
the research of the antigens of Candida genus fungi and 
development of vaccines against candidiasis have never 
stopped abroad, and in many countries on the territory of 
the former Soviet Union these studies are renewed and 
carried out actively [15, 20, 22, 25]. It is worth 
mentioning that currently no domestic vaccine is 
produced in Ukraine for prevention and treatment of 
candidal infection and no imported vaccines have been 
registered.  
At first to develop a vaccine against candidiasis 
it is necessary to analyze the data obtained by previous 
researchers and to check some of them. It is known that 
the use of the attenuated cells of Candida genus fungi, 
i.e. live vaccines, is impractical in connection with 
impossibility of standardization and a possible activation 
of the causative agent. It is also not appropriate to use 
products of cell metabolism of Candida genus fungi 
since the biochemical composition of metabolites differs 
from the composition of the substances contained in the 
composition of the cells of Candida genus fungi, and 
therefore, they do not provide the necessary immune 
reactions. When developing a vaccine for prevention and 
treatment of candidal infection it is expedient to use 
inactivated cells of Candida genus fungi; to develop a 
dead vaccine. Some components of the cells of Candida 
genus fungi, namely proteins and carbohydrates, can be 
used for subunit vaccines. For the final choice of the type 
of the vaccine required it is necessary to develop the 
technology for their obtaining and to study immune 
responses. 
The technology of development of a dead and 
subunit vaccine for prevention and treatment of candidal 
infection supposes cultivation of Candida genus fungi, 
and on their basis development of vaccines is planned. 
That is why the primary task is to substantiate the 
technological mode for cultivation of Candida genus 
fungi.  
To develop a candidal vaccine it is necessary to 
determine strains or species of microorganisms, which 
are the most widespread or main causative agents of 
candidal infection. According to the literature data in 
species identification of the fungi taken from the patients 
with candidal infection it has been found that practically 
in all cases the fungi of C. albicans species are the 
causative agents of the disease. The second widespread 
species is C. tropicalis occurring, as a rule, in association 
with C. albicans. In some cases C. parapsilosis, C. 
glabrata and C. krusei have been also determined in 
association with C. albicans or C. albicans and C. 
tropicalis) [2, 4, 20, 25]. Thus, conducting the research 
with the species of C. albicans and C. tropicalis is 
promising for development of a combined vaccine [2, 
30]. 
Therefore, summarizing the above said the 
conclusion can be made that the research concerning 
development of vaccine against candidiasis is the topical 
issue of modern pharmacy and medicine. 
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UDC 615.371:616-097:616.992.282 
BIOTECHNOLOGICAL DESCRIPTION OF 
TECHNOLOGIES FOR OBTAINING OF 
ANTIGENS OF CANDIDA GENUS FUNGI 
Rybalkin М.V. 
To develop the vaccine against candidal infection the 
various biotechnological methods for obtaining antigens 
of Candida genus fungi have been considered in the 
article. To obtain antigens for the prevention and 
treatment of candidiasis researchers use different types 
and parts of fungi of the genus Candida. Methods of 
preparation of antigens also vary widely including 
chemical, physical and physico-chemical techniques. Of 
all possible variants development and research of a dead 
and subunit vaccine based on C. albicans and C. 
tropicalis fungi that are the main causative agents of 
candidiasis have been chosen for further study.  
Key words: candidiasis; antigen, vaccine, immunity 
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ОСВІТЛЕННЯ ТЕХНОЛОГІЙ ОДЕРЖАННЯ 
АНТИГЕНІВ ГРИБІВ РОДУ CANDIDA 
Рибалкін М. В. 
У даній статті були розглянуті різні біотехнологічні 
методи одержання антегенів грибів роду Candida для 
розробки вакцини проти кандидозної інфекції. Для 
одержання антигенів для попередження та лікування 
кандидамікозу дослідники використовують різні 
види та частини грибів роду Candida. Методи 
одержання антигенів також широко варіюють 
включаючи хімічні, фізичні та фізико-хімічні 
прийоми. З усіх можливих варіантів для подальших 
досліджень було обрано розробка та дослідження 
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убитої та суб'єдиничної вакцини на основі грибів C. 
albicans та C. tropicalis, які є основними збудниками 
кандидамікозів.  




ОСВЕЩЕНИЕ ТЕХНОЛОГИЙ ПОЛУЧЕНИЯ 
АНТИГЕНОВ ГРИБОВ РОДА CANDIDA 
Рыбалкин Н. В. 
В данной статье были рассмотрены различные 
биотехнологические методы получения антегенив 
грибов рода Candida для разработки вакцины против 
кандидозной инфекции. Для получения антигенов 
для предупреждения и лечения кандидамикоза 
исследователи используют различные виды и части 
грибов рода Candida. Методы получения антигенов 
также широко варьируют включая химические, 
физические и физико-химические приемы. Из всех 
возможных вариантов для дальнейших исследований 
были выбраны разработка и исследование убитой и 
субъединичной вакцины на основе грибов C. albicans 
и C. tropicalis , которые являются основными 
возбудителями кандидамикоз. Оба варианта вакцины 
предусматривают накопление биомассы грибов на 
основе которых и планируется разработка вакцин. 
Ключевые слова: кандидамикоз; антиген; вакцина; 
иммунитет 
 
 
